Evidence map›Paper›PMID 42066750›Full record

ArticleCell2026

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Luca Gattinoni, Gabriele Inchingolo, Dennis C Harrer, Alberto Susana, Simone Puccio, Dragana Slavkovic-Lukic, Danielle A Natrakul, Nicholas Strieder, Christoph Heuser-Loy, Jeremy G Baldwin and 21 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01087294 (Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01087294 phase1completednot on this map

Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2010 to 2024Enrolled85ConditionsLeukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-CellArmsAllogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Luca GattinoniDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; University of Regensburg, Regensburg, Germany; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. Electronic address: luca.gattinoni@lit.eu.
Gabriele InchingoloDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Dennis C HarrerDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Alberto SusanaIRCCS Humanitas Research Hospital, Rozzano, Italy.
Simone PuccioIRCCS Humanitas Research Hospital, Rozzano, Italy; Institute of Genetics and Biomedical Research, Milan Unit, Consiglio Nazionale delle Ricerche, Rozzano, Italy.
Dragana Slavkovic-LukicDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Danielle A NatrakulSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nicholas StriederNext Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Christoph Heuser-LoyDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Jeremy G BaldwinDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Jessica FioravantiDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yun JiCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sanjivan GautamCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Chiara SurianoEpigenetic Immuno-Oncology Group, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Azucena Martín-SantosDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Roland C SchelkerDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Nisha PatelHematology Section, Department of Laboratory Medicine, National Institutes of Health, Clinical Center, Bethesda, MD, USA.
Jennifer MannSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephanie GoffSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Lekha MikkilineniDivision of Bone and Marrow Transplantation & Cellular Therapies, Stanford University School of Medicine, Palo Alto, CA, USA.
James C YangSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mei Li M KwongSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rashmika PatelCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael RehliDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Steven L HighfillDepartment of Transfusion Medicine, National Institutes of Health, Clinical Center, Bethesda, MD, USA.
David F StroncekDepartment of Transfusion Medicine, National Institutes of Health, Clinical Center, Bethesda, MD, USA.
Steven A RosenbergSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Luca BiascoFaculty of Population Health Science, Department of Infection Immunity and Inflammation, Zayed Centre for Research, University College of London, London, UK.
Enrico LugliIRCCS Humanitas Research Hospital, Rozzano, Italy.
Jennifer N BrudnoSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James N KochenderferSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: kochendj@mail.nih.gov.

Funding

Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen ReceptorZIABC011415 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOCHENDERFER, JAMES · 2011 to 2025
$2.0M
Intramural NIH HHS ZIA BC011415
6 · The paper itself

Abstract

Donor-derived CD19-CAR T cells offer a therapeutic option for B cell malignancies relapsing after allogeneic hematopoietic stem cell transplantation but are often constrained by poor engraftment, expansion, and persistence. In a first-in-human study (NCT01087294), we found that CAR-modified stem-cell memory T (T

Indexed as

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveMemory T CellsStem CellsT-LymphocytesAntigens, CD19FemaleHumansImmunologic MemoryMaleReceptors, Chimeric AntigenRecurrenceTissue DonorsTransplantation, HomologousAntigens, CD19Receptors, Chimeric AntigenB cell malignanciesCAR T cellsdonor-derived T cellsPhase 1 studystem cell memory T cells

Identifiers

PMID42066750
PMCPMC13289710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.